• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by AVEO Pharmaceuticals Inc.

    1/30/23 4:07:52 PM ET
    $AVEO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVEO alert in real time by email
    15-12G 1 d389181d1512g.htm 15-12G 15-12G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

    Commission File Number 001-34655

     

     

    AVEO Pharmaceuticals, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    30 Winter Street

    Boston, Massachusetts 02108

    (857) 400-0101

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Common Stock, Par Value $0.001 Per Share

    (Title of each class of securities covered by this Form)

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)    ☒
    Rule 12g-4(a)(2)    ☐
    Rule 12h-3(b)(1)(i)    ☒
    Rule 12h-3(b)(1)(ii)    ☐
    Rule 15d-6    ☐
    Rule 15d-22(b)    ☐

    Approximate number of holders of record as of the certification or notice date: One (1)

    Pursuant to the requirements of the Securities Exchange Act of 1934, AVEO Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

        AVEO PHARMACEUTICALS, INC.
    Date: January 30, 2023     By:  

    /s/ Michael Bailey

        Name:   Michael Bailey
        Title:   President and Chief Executive Officer

     

     

     

    Get the next $AVEO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVEO

    DatePrice TargetRatingAnalyst
    11/8/2022$15.00Buy → Hold
    Stifel
    7/12/2021$27.00 → $19.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AVEO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 2024 Entrepreneurship Summit Presented by the Harvard Undergraduate Venture Capital Group: Agenda and Speakers

      The Harvard Undergraduate Venture Capital Group (VCG) will hold its annual Entrepreneurship Summit on Sunday, March 24, 2024, from 8 AM to 5:30 PM at The Ritz-Carlton in Boston. The Summit is the largest undergraduate entrepreneurship and venture capital conference in the nation and will bring together founders of unicorn startups, CEOs of public companies, and renowned venture capital and private equity investors. The event will convene over 55 speakers and 15 panels on Leadership, Investing, and Entrepreneurship with Advanced Tracks discussing topics ranging from biotech to investing in AI. Keynote speakers include: Steve Kraus, Partner at Bessemer Venture Partners and world-renown

      3/22/24 6:14:00 PM ET
      $BEAM
      $DASH
      $LYFT
      $AVEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Business Services
      Consumer Discretionary
    • LG Chem Completes Acquisition of AVEO Oncology

      SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. ("LG Chem") (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology ("AVEO"), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, in an all-cash transaction with an implied equity value of $571M on a fully diluted basis. "We are excited to complete LG Chem's acquisition of AVEO, which will position us to deliver on our mission of becoming one of the world's leading oncology companies with a robust clinical pipeline of innovative therapies," said Shin Hak-Cheol, Chief Execu

      1/19/23 4:35:03 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AVEO Oncology Stockholders Approve Acquisition by LG Chem

      BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology ("AVEO") (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders (the "Special Meeting") held today, AVEO stockholders approved the adoption of the Agreement and Plan of Merger among LG Chem, Ltd. ("LG Chem"), a subsidiary of LG Chem and AVEO (the "merger agreement"). As previously announced, under the terms of the merger agreement, AVEO stockholders will receive $15.00 per share in cash upon the closing of the transaction. "Today's approval is a significant step toward the c

      1/5/23 7:35:35 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care